Agenda (with session objectives)

This hybrid program will be released June 1-3, 2022 giving registrants the option of attending live (in-person) or virtually (livestream). Later, from June 9 to July 29, the full program will remain available for on-demand viewing to all who register for either live or virtual attendance.

To secure a CEU/CME certificate for all sessions attended, individuals will be directed to complete an evaluation form for each session as well as one overall program evaluation. The program, including the pre-conference, offers up to 39.25 hours of continuing education credits in most fields.

JUMP TO AGENDA FOR THURSDAY, JUNE 2

JUMP TO AGENDA FOR FRIDAY, JUNE 3

WEDNESDAY, JUNE 1, 2022

OPTIONAL PRE-CONFERENCE WORKSHOP

12:30 pm

REGISTRATION & CHECK-IN

1:00 - 5:00 pm

Evaluator Workshop:
AN INTERACTIVE APPROACH TO THE EVALUATION & TREATMENT NEEDS OF HEALTHCARE PROFESSIONALS

Kelli Jacobsen, LCSW
Robert Simpson, MD, FASAM
Spencer K. Hansen, MD

The Utah Professionals Health Program (UPHP) was created by the Division of Occupational and Professional Licensing (DOPL) to provide an alternative to public discipline and to assist licensed healthcare professionals whose ability to practice may be impaired due to a substance use disorder. In order to fulfill our mission, we are in need of evaluators who can properly evaluate potential participants of the program. This workshop will build upon the previous workshop held in November, 2021. Attendance at the previous training is not required. However, videos of the previous training will be made available to all who register for this training. Join this program and run a case study and work in small groups to formulate assessment findings and recommendations.

After this interactive experience, participants will be able to:
(1) Explain the UPHP and how it works, from reporting to monitoring as well as key differences in evaluating safety sensitive healthcare providers versus the general population; and,
(2) Apply emerging best practices in the treatment of healthcare professionals in the clinical setting.

Suggested readings for this workshop

THURSDAY, JUNE 2, 2022		Jump down to agenda for Friday, June 3
8:00am	REGISTRATION & CHECK-IN
8:30am	WELCOME & ADMINISTRATION Elizabeth F. Howell, MD \| CME Course Director, University of Utah Department of Psychiatry
	Keynote Address: PHARMACOLOGIC TREATMENTS FOR STIMULANT USE DISORDERS: WHAT DOES THE TREATMENT LITERATURE TELL US? Frances R. Levin, MD	_{Stimulant use is a rising public health problem that is associated with substantial individual and societal costs including the development of use disorder and overdose deaths. Less than a third of individuals with stimulant use disorders (StUD) receive treatment and many have underlying psychiatric disorders that also goes untreated. Moreover, some individuals using stimulants are inadvertently or intentionally using opioids, exacerbating the risks of overdose deaths. Comprehensive treatment strategies that incorporate evidence-based interventions need to be implemented if treatment is to be successful. Unfortunately, for some, existing treatments remain inadequate and novel interventions need to be considered. Whereas there are FDA-approved treatments for alcohol and opioid use disorders, there are no FDA-approved medications for the treatment of StUD. However, there are several medications that show promise and may have therapeutic benefit for those who have not responded to standard treatments. The potential benefits and careful use of these medications will be discussed. Once participants have heard this presentation, they will be able to: (1) Present the pharmacologic strategies’ approaches utilized to test treatments of stimulant use disorders; and, (2) Pick up what pharmacologic strategies show promise for the treatment of stimulant use disorders and explain the methodologic and practical limitations of current research impeding discovery of an FDA-approved medication for cocaine use disorders.}
9:45am	BREAK
10:00am	Session #1 TREATMENT OF ADHD & SUBSTANCE USE DISORDERS Frances Levin, PhD	_{After hearing this presentation, participants will be able to: (1) Explain the nuances which must be considered when treating substance abuse disorders among individuals with ADHD; and, (2) Discuss device-based pharmacologic interventions and its applications with these individuals.}
10:00am	Session #2 THE RISE OF FENTANYL IN UTAH: OVERDOSE & ADDICTION Michael Moss, MD	_{Fentanyl deaths in Utah doubled from 2019 to 2020. Highly potent and easy to overdose on, it may be found in counterfeit oxycodone as well as the heroin supply, many patients are unknowingly using fentanyl. As use rises in Utah and around the country, raising public awareness is key along with collaboration between healthcare providers, public health, and law enforcement. After attending this presentation, participants will be able to: (1) Explore how fentanyl – in its many forms and combinations, is changing the treatment landscape as well as the world of misuse and abuse; and, (2) Outline the existence of fentanyl in most substances, the subclasses, analogs, various reaction, detection and treatment protocols in appropriate clinical situations and when misuse/abuse has occurred.}
10:00am	Session #3 HARM REDUCTION IN UTAH & BEYOND Mark Bigler, LCSW, PhD; Dusti Jordan, BSW	_{Harm Reduction, successfully implemented in various countries for decades, is beginning to gain traction in the U.S.. We will explore a little of the history of Harm Reduction, the possible pros and cons, discuss the research surrounding the intervention, current local and national policies, and how you can support Harm Reduction in your community. After listening to the insights of these speakers, attendees will be able to: (1) Explain the current harm reduction programs and concepts and the literature about these programs; and, (2) Argue the pros and cons of these programs and the components required to make them successful.}
10:00am	Session #4 THE RECOVERY RESILIENCE PROGRAM: A NOVEL RELAPSE PREVENTION & ADDICTION RECOVERY PROGRAM Guy du Plessis, MA; Kevin G. Webb, LCSW	_{Our presentation provides an brief overview of a novel relapse prevention and addiction recovery intervention called the Recovery Resilience Program (RRP). The RRP is an application of Mind-Body Bridging and was developed at the I-System Institute for Transdisciplinary Studies, Utah State University. At the core of a RRP are coping and self-regulations skills, called recovery resilience skills. The practice of recovery resilience skills builds “recovery resilience,” which we conceptualize as an individual’s capacity to successfully apply coping skills in dealing with high-risk situations, without reverting to substance use, and their ability to self-regulate without the use of substances. The concept of recovery resilience has commonality to the notion of “recovery capital,” a phrase used in recovery communities to refer to the total internal and external resources that a person has available to find and maintain their recovery process. Recovery resilience relates to the internal resources of the individual. The aim of participating in a RRP is for people in recovery to develop a recovery resilience practice that will strengthen their internal resources, therefore contributing to their overall recovery capital, as well as promoting flourishing. As a result of participating in this presentation, participants will leave able to: (1) Provide a theoretical overview of recovery resilience and the importance of approaches using person-centered, strength and resiliency-based components; and, (2) Incorporate the skills included in recovery resilience proven to be most effective.}
11:00am	BREAK
11:15am - CANCELLED SESSION	Session #1 - CANCELLED SESSION BENEFITS OF INTEGRATION OF CPS WITH CARE COORDINATION INTO HEALTH CARE SETTINGS Brett S. Bartruff, LCSW	CANCELLED SESSION _{The use of peer supports is a successful intervention to coordinate and establish care for patients needing behavioral health services and other case management needs. This presentation will offer several examples of programs throughout the state that utilize peer supports to respond to patient needs in several health care settings. Attendees will receive information for peer supports throughout the state that can be accessed by their healthcare organization After gaining information from this session, participants will be able to: (1) Provide an overview of how the use of peers is growing and how their future appears to be heading towards more involvement in case management in various settings (i.e. in- and out- patient, emergency departments, recovery programs); and, (2) Explore how peers can be used in their own practice settings to help improve client compliance and outcomes.}
11:15am	Session #2 BUPRENORPHINE TREATMENT FOR OPIOID USE DISORDER: PAST, PRESENT & FUTURE DIRECTIONS Adam J. Gordon, MD, MPH	_{During this presentation we will discuss various ‘hot topics’ in buprenorphine treatment for opioid use disorder. We will discuss the trends in treatment strategies in both addiction and non-addiction health care environments. We will discuss new formulations of buprenorphine, including new injectable formulations. “Clinical case conundrums” will be presented for discussion. Ample time will be available for questions. After participating in this program, participants will be able to: After attending this program, participants will be able to: (1) Trace buprenorphine treatment for opioid use disorders has evolved in the U.S. and discuss new formulations of buprenorphine, including injectable forms that are being used to enhance access to opioid use disorder medication treatment; and, (2) Discuss new means to initiate or maintain buprenorphine care, including practices such as low dose buprenorphine initiation (LDBI) and maintenance of buprenorphine I the perioperative period.}
11:15am	Session #3 STREET TRENDS HITTING OUR COMMUNITIES & CLIENTS Joshua Allred, Sgt	_{Drug trends in the United states are ever changing. It is important to realize the impacts that drugs have both on our youth and on our communities. We will discuss the current drugs that are impacting our communities as well as describe their physical make-up and effects on the use. After attending this session, participants will be able to: (1) Educate the public on current drug trends in the United States; and, (2) Outline the physical appearance of illegal narcotics and discuss their effects on the users.}
11:15am	Session #4 NICOTINE IN TREATMENT, WHAT’S THE BIG DEAL? Spencer Baker, LCSW Suggested readings for this session	_{The neglected epidemic, nicotine use in treatment. Is it really that big of a deal? Join this presentation and learn about the research, common myths, assessments, and nicotine replacement therapy for nicotine use and how to talk to clients. After listening to these presenters, participants will be able to: (1) Present the pro and con arguments of allowing nicotine use during treatment and the common myths and barriers associated with nicotine use during treatment; and, (2) Translate these arguments and the corresponding research to policies in various levels of care, demonstrate monitoring and management needs, discuss provider buy-in to policies based upon science versus ‘marketing’ of their services, and cover Medicare and insurance standards in this area.}
12:30pm	LUNCHEON
12:30 - 1:00pm	UTSAM CHAPTER MEETING	*Open to members and interested individuals*
1:15pm	Session #1 THE ‘METHAMFENTANYL’ WAVE: TARGETED TREATMENTS TOWARDS THE METHAMPHETAMINE PIECE Javier Ballester, MD	_{Last year the USA suffered from the highest number of overdoses by drugs in history (˂100,000 people). Methamphetamine use has been one of the main actors fueling this unprecedented catastrophe. After briefly reviewing the differences in the distribution of psychostimulant problems across the nation, we will review the current and most evidence-based interventions in the treatment of methamphetamine use disorder, including both psychosocial and psycho-pharmacological approaches, with a brief look into different interventions in development. We will finally understand the need to implement harm reduction strategies, using different guidelines from national organizations, and to individualize these treatments to minority populations that are being disproportionally affected by this tragedy. As a result of attending this program, individuals will be able to: (1) Review differences in epidemiological distribution of methamphetamine addiction in the USA and the role that methamphetamine is playing in fueling the latest wave of the opioid epidemic national crisis; then, (2)Explain the current, most evidence-based psychobiological treatments in meth use disorder, harm reduction strategies, and the impact of meth on minorities.}
1:15pm	Session #2 E MERGING TRENDS IN THE TREATMENT OF ADDICTIVE DISEASE FOR THE LGBT POPULATION Ejay Jack, MPA, LCSW; Mason S. Turner, MD	_{While the LGBTQ community is diverse and dynamic, and members of the community require individual approaches to evaluation and treatment for addictive disease, certain common cultural themes exist for much of the community that should be considered in developing the most culturally sensitive and effective treatment approaches. This presentation will focus not only on culturally appropriate language to employ in the evaluation of consumers from the community who are seeking treatment but will also discuss specific cultural approaches that will lead to more effective interventions and enhance the probability that consumers will remain in care. Additionally, the presenters will assist learners in understanding the unique lifelong psychological dynamics for the community that will enhance learners’ ability to engage empathically with the community. After spending time with this speaker, participants will be able to: (1) Outline specific ethical, legal, and inclusive considerations which must be addressed when providing services to LGBTQIA+ individuals – from terminology to appropriate services, from physical settings to appropriate discharge and aftercare; and, (2) Develop an approach to the assessment of substance use disorders in the LGBTQ community that is focused on cultural considerations that may precede or accelerate development of addictive disease, including early exposure to psychological trauma and discrimination as well as familial distress. Also, be able to Include adaptations to treatment plans and environments which address this identified consideration at all levels of intervention.}
1:15pm	Session #3 CRAFT – A FAMILY PEER MODEL OF FAMILY SUPPORT FOR ADDICTION RECOVERY Jennifer B. Slack, BA; Darlene Schultz, BS Suggested readings for this session	_{Learn about USARA's free structured non-clinical program to support family members and friends who have loved ones that struggle with substance use. USARA uses a peer-facilitated model based on Community Reinforcement and Family Training (CRAFT) and runs concurrently in a cycle of 12-week sessions. The weekly group meetings are available both in-person and online with no charge ot participants for the class or materials. The CRAFT model is a non-confrontational approach that identifies behavioral principles like reinforcement and provides family members with tools and instructions for changing interactions with loved ones, which in turn helps change the loved one's behavior. Positive reinforcement and kindness are powerful tools of change. After this session, you will be able to: (1) Explore the research supporting community reinforcement and family training components in the substance use treatment and recovery arenas and the specific components of CRAFT after viewing a 'mini-craft group demo' on positive communication; and (2) Explain the basic structure of the CRAFT Family Support Program and be able to share the importance of family recovery.}
1:15pm	Session #4 DENTAL APPROACH TO SUD TREATMENT OUTCOME MITIGATION Glen R. Hanson, DDS, PhD	_{Oral health problems are a common issue with most major SUD conditions. Based on the assumption that comprehensive management of these SUD-related poor dental condition will positively impact the success of treatment for SUDs, we partnered with local SUD treatment programs (i.e. First Step House and Odyssey House) to test this hypothesis. This presentation includes the findings of this study referred to as the FLOSS program, which demonstrated that integrated oral health care dramatically increased SUD treatment time, drug use abstinence and employment in persons experiencing SUD programs associated with heroin, methamphetamine and alcohol use disorders. This presentation discusses how the FLOSS findings were used to create a unique Dental program for Medicaid adults being treatment for their substance use problems. After joining this expert, participants will be able to: (1) TBD (2) TBD}
2:15pm	BREAK
2:30pm	Session #1 HORMONES & SUBSTANCE USE DISORDER – SEX (AND HAVING IT), MATTERS Amy de la Garza, MD, IFMCP, Board Eligible Addiction Medicine	_{Men and women experience initiation, maintenance and recovery from SUD differently, and research regarding these differences is somewhat limited. However, it is worthwhile to explore these hypotheses and ideas to provide context to the treatment of men and women. Substance use disorder affects hormones including cortisol, thyroid and sex hormones in a myriad of ways, which are important to understand in the context of providing holistic and integrated care for patients. Sex hormone optimization in perimenopausal and menopausal women is an important component of care for women with SUD and behavioral health diagnoses, as well as addressing opioid induced androgen deficiency in men undergoing treatment with medications for opioid use disorder. After attending this presentation, you will be able to: (1) Discuss sex differences in development, maintenance and recovery from SUD as well as the effects of SUD on cortisol, thyroid and sex hormones; and, (2) Explore the role of cortisol, thyroid and sex hormone optimization as an integrative approach to SUD treatment.}
2:30pm	Session #2 HEROIN, PILLS, IT ALL KILLS. PROGRAMMING, PARTNERSHIPS & LESSONS LEARNED FROM UTAH NALOXONE Jennifer Plumb, MD, MPH Suggested readings for this session	_{This session will provide an overview of Utah Naloxone’s mission, vision, and evidence-based programming. Utah’s Naloxone’s policy priorities and advocacy efforts will be discussed along with partnerships and high-impact naloxone distribution strategies. Drug user health strategies will be discussed, and case studies reviewed. Participants in this session will leave able to: (1) Outline some of the key ‘lessons learned’ since the development of naloxone and programs to implement its use; and, (2) Discuss the need for, and roles of, partners in these efforts, and outline the most current knowledge around the use of naloxone.}
2:30pm	Session #3 TO KRATOM OR NOT TO KRATOM, THAT IS THE QUESTION Steve Sugden, MD, MPH, FASAM, DipABLM	_{With the rise in Kratom use, many providers need to educate themselves about the potential harms in order to better provide treatment for their patients. Providers will gain an understanding of potential risks of Kratom use and how to provide treatment. Upon leaving this session, attendees will be able to: (1) Discuss and contrast the therapeutic benefits with the negative effects of kratom and other ‘designer drugs’ currently sweeping across the U.S.; and, (2) Recognize and assess the effects of the use of these substances and author a treatment plan which addresses the specific needs of these users.}
2:30pm	Session #4 OUR FUTURE – OUR PROVIDERS: WHAT’S HAPPENING IN POST-SECONDARY EDUCATION? Michael E. Dusoe, PhD, LCSW; Zoe Robbins, DNP, PMH-NP; Angelea Panos, PhD, MA, MSW; Cory Dennis, PhD, LCSW	_{This panel discussion hopes the audience will learn about the current curriculum being taught to future behavioral workforce students specific to the addiction disorders patient population. The discussion will include areas of strength in specific schools / programs and potentially identify opportunity for increased and/or improved curriculum in our current social work, psychology and advanced practice clinician schools. As a result of attending this session, participants will be able to: (1) Identify the gaps, needs and efficacy issues currently existing in the post-secondary programs for addiction treatment professionals; and, (2) Discuss how the current programs in Utah will impact related workforce and brainstorm solutions to the identified weaknesses.}
3:45pm	BREAK
4:00pm	Session #1 THE ROLES WE PLAY Amy Miner, LCMHC	_{Parents often feel alone, isolated and on an emotional roller-coaster when they suspect or learn that their teen is / may be using substances. Join this session and examine the roles parents play at these times. Learn how to help parents better understand these roles, shift roles and keep the relationship in-tact while determining next steps and treatment needs. After hearing from this practitioner, participants will be able to: (1) Outline the basic concepts associated with relationship roles and explain why these roles matter when substance abuse is suspected or confirmed; and, (2) Provide a framework of these concepts to parents who are making decisions about therapy / treatment needs for their kids/teens.}
4:00pm	Session #2 HEPATITIS C ELIMINATION & ADDICTION MEDICINE Terry D. Box, MD Suggested readings for this session	_{Blood-borne viral hepatitis infections are very common in the injecting drug user community. It is estimated that 40% of injection drug users have hepatitis C. 70% of new hepatitis C infections in the United States are linked to injection drug use. Addiction Medicine providers are key participants in screening for and linking to care / treating hepatitis C. To meet the World Health Organization goal of eliminating hepatitis C as a significant public health issues, Addiction Medicine providers will have to play a critical role. This presentation will review the epidemiology of HCV, the demographics of the current HCV epidemic and discuss screening and how to assess and treat those who are diagnosed with hepatitis C. Once participants have completed this session, they will be able to: (1) Trace the back-and-forth connections of substance use/abuse and communicable diseases; and, (2) Identify the ‘gaps’ in systems designed to assist these individuals and how community partnerships and integrated care can positively impact these scenarios.}
4:00pm	Session #3 GENETICS OF SUBSTANCE USE DISORDERS Emily DiBlasi, PhD	_{Recent genetic studies have established that most psychiatric disorders, including substance use disorders (SUDs), are highly polygenic and pleiotropic. This means that thousands of risk alleles across the genome contribute to a person’s overall level of risk or protection in developing these disorders and that many risk alleles are shared across multiple disorders. However, genetic discovery in SUDs is still in the beginning stages and we are very far from widespread clinical application of these data. Currently, only a fraction of the genetic variation influencing SUDs has been accounted for, but the continued discovery of more risk loci will improve our knowledge of addiction biology. An overview of genetic findings for the main SUD phenotypes (alcohol, tobacco, opioids, cannabis and cocaine) will be given and potential areas for future clinical application will be discussed. After leaving this second presentation by this speaker, participants will be able to: (1) Outline some of the current research directions and findings around genetics and addictions; and, (2) Consider these findings in developing treatment plans and present some of the potential future implications and directions in the fields of genetics and addiction.}
4:00pm	Session #4 MARIJUANA UPDATES – PREVENTION, POLICY & TREATMENT Clifton R. Uckerman, LCSW Suggested readings for this session	_{Clif was an early advocate and ally for prop 2 legislation, medicinal use of cannabis, and early adopter of medicinal cannabis in mental health and substance use treatment for PTSD in the behavioral health and addiction treatment industry. An original provider and pioneer for the expansion of behavioral health services in the medical cannabis industry and medical cannabis community. He has drawn from existing literature and research related to use of cannabis for PTSD and is using qualitative study and anecdotal research to understand the key benefits of medical cannabis in conjunction with PTSD treatment to improve the quality of service delivery for medical cannabis subscribers with PTSD and to offer medical cannabis as an adjunct or alternative to traditional treatment for patients with mental health and addiction problems. Clif will present key findings, best practice and positive outcomes. After listening to this expert, individuals will leave able to: (1) Trace the state and national trends regarding use and policies around marijuana including the projected future trajectories; and, (2) Outline the research, prevention, and intervention concepts around marijuana for various populations and uses.}
5:00	END OF DAY ONE

FRIDAY, JUNE 3, 2022		Jump up to agenda for Thursday, June 2
8:00am	CHECK-IN
8:30am	WELCOME BACK! Utah Department of Professional Licensing (DOPL) Utah Division of Substance Abuse & Mental Health
	Keynote Address: THE PROTECTIVE WALL OF HUMAN COMMUNITY: WHAT DOES THE SCIENCE TELL US ABOUT THE CLINICAL & PUBLIC HEALTH UTILITY & MECHANISMS OF AA & TWELVE-STEP TREATMENT? John F. Kelly, PhD Suggested readings for this session	_{Alcohol and other drug use disorders are the top public health problem in most middle and high income countries around the world. To address these challenges, most societies provide a variety of formal professionally directed treatment and recovery support services as well as a cadre of community-based recovery support options. Alcoholics Anonymous is by far the world's largest addiction recovery support organization and professional treatments have been developed and implemented to link patients with these resources to help prevent relapse and sustain remission. Until recently, little was known from a rigorous scientific standpoint regarding the efficacy of clinically delivered treatments designed to engage patients with AA (so called, Twelve-Step Facilitation [TSF] treatments) or the effectiveness, cost-effectiveness of AA and the therapeutic mechanisms through which AA confers benefits. This talk will review the latest science on AA, TSF treatments, cost-benefits, and mechanisms, and discuss the implications for clinical implementation. After attending the session, participants will be able to: (1) Describe the state of the science on AA, 12-step treatments, and cost-effectiveness along with the three major therapeutic mechanisms through which AA has been shown to confer recovery benefits; and, (2) Discuss how AA can work differently for different people despite conferring similar magnitude of benefit.}
9:30am	BREAK
9:45am	DEVELOPING A SHARED LANGUAGE FOR DIVERSITY, EQUITY AND INCLUSION IN SUBSTANCE USE DISORDER TREATMENT & RECOVERY* Deena M. Murphy, PhD *This presentation offers 0.5 hours of ethics credits	_{Developing a Shared Language for Diversity, Equity and Inclusion in Substance Use Disorder Treatment and Recovery will provide you with an opportunity to enhance your knowledge and awareness of diversity, equity, and inclusion (DEI) issues. We will explore the potential impact of these issues on our beliefs towards those with backgrounds different from our own and how those beliefs can impact the people we serve and the continuum of care for substance use disorder. This training is an opportunity o reflect on ways to create more welcoming and inclusive places of business for our staff and clients, as well as look at ways organizations can support DEI efforts. This behavioral specialist will provide information which will allow participants to: (1) Review baseline language to ground us in a shared understanding of DEI issues and social determinants of health and explore equity data on the impact of DEI issues on health care access, experiences, and outcomes and unpack myths of DEI and those impacted by these issues; and, (2) Review situational examples and their implications for opioid, stimulant, and substance use disorder treatment and recovery and identify ways to practice cultural humility and engage in DEI work both individually and organizationally.}
11:00am	BREAK
11:15am	Session #1 ADDICTIONS UPDATE: GERIATRICS Bryon Bair, MD, FACP, MBA	_{The aim of this session is to present, discuss and consider relevant addiction demographics, risk factors, physiological issues, interventions and treatment considerations for geriatric populations. Upon completion of this presentation, participants will be able to: After attending this program, attendees will leave able to: (1) Trace some common paths of substance use, misuse, and abuse in older adults and the ‘red flags’ providers should be able to recognize; and, (2) Diagram the brain changes in these individuals and correlate those changes to behavior, cognition, ADLs, and other functions..}
11:15am	Session #2 MUCH ADO ABOUT TRAUMA: THE CONNECTION WITH SUD’S Kate Speck, PhD, MAC, LADC	_{Whether seeking substance use treatment voluntarily or having treatment mandated, individuals are likely to have a history of trauma. The relationship between increased trauma exposure and substance use is undeniable as is the severity of increased experience of trauma and the increase in severity of substance abuse and negative health outcomes. Despite these well-known facts, only a quarter of substance abuse treatment programs are offering evidence based trauma services. This presentation will describe pathways between trauma and addiction, the impact of countertransference on treatment providers, effective treatment strategies and review supportive policies for trauma informed care in substance use treatment. Upon completion of this presentation, participants will be able to: (1) Identify paths from trauma to addiction disorders and the overlapping neurobiology of trauma and SUDs as well as the issues of countertransference working with trauma clients; and, (2) Describe effective strategies to increase treatment outcomes and review policies that support trauma informed care in SUD treatment.}
11:15am	Session #3 CREATING A BRIDGE OVER TROUBLED WATERS – ACCESSING OPIOID USE DISORDER TREATMENT IN EMERGENCY DEPARTMENTS Sara Phillips, MBA, BSN, CPHQ	_{This presentation will focus on the development of an evidence-based guideline, initiated in the Emergency Department, and designed to create a bridge to treatment for opioid use disorder patients and promote implementation of best practices for prevention of opioid overdose. The presenter will share the impetus for development of the Utah Guide for Management of Opioid Use Disorder, the content of the resource, the current stage of implementation and the barriers that have been identified. The Utah Guide, modeled after the Levels of Care for Rhode Island Emergency Departments and Hospitals for Treating Overdose and Opioid Use Disorder, provides for three levels of standardized care. We will share the evidence-based elements in Level 3, Level 2, and Level 1. A link in the Guide itself and the self-assessment tool will be provided to conference attendees. After attending this presentation, you will be able to: (1) Present the roll-out of Comagine’s state partnerships and the expected outcomes in levels of care and hospital engagement; and, (2) Discuss the levels of care for overdose and opioid use disorder in hospital emergency department visits and how community resources can be accessed and utilized in both urban and rural areas.}
12:30pm	LUNCH
1:30pm	Session #1 HIGH STAKES DECISIONS & THEIR CONSEQUENCES: A LOOK AT ETHICAL REASONING, MORAL INJURY, AND SELF-CARE. Ashley Greenwell, PhD *This presentation offers 1.25 hours of ethics credits	_{When making judgments in complex and high-stakes situations, there is a heightened risk of sustaining a moral injury. This can occur when healthcare workers, soldiers, and others are forced to act (or not to act) in ways that go against their own conscience, when they must make a call despite unresolved inner turmoil, or when they perceive that others are engaging in grave ethical violations. This presentation will explore the continuum f moral emotions, human decision-making, as well as the concepts of moral distress and injury. It will review causes and examine why traditional trauma treatments may be ineffective for individuals facing this type of issue, as well as review practical intervention options for healing. After attending the session, participants will be able to: (1) Translate the concept of moral injury into common cognitive and emotional responses which may present and be able to uncover the cause of the injury in order to identify the issues which must be addressed in clinical interventions; and, (2) Write and follow a treatment plan for individuals who have experienced a moral injury and evaluate the progression of the treatment in order to adjust its course as may be indicated.}
1:30pm	Session #2 OVERDOSE & SUICIDE DEATHS FROM THE MEDICAL EXAMINER PERSPECTIVE Megan Broekemeier, CHES; Michael J. Staley, PhD *This presentation offers 1.25 hours of suicide prevention credits	_{Drug overdose and suicide rates remain high in Utah. A critical first step in addressing any public health concern is understanding the problem. Data collected from the Medical Examiner’s Office (OME) will demonstrate how big these problems are, where the burden is the worst, and who is impacted. Additionally, data collection methods employed by the OME to understand “why” will be discussed. Attendees will leave with a better understanding of drug overdose and suicide mortality in Utah and how data collected by the OME are being used to help prevent future tragedy. After hearing this presentation, participants will be able to: (1) Provide the current state picture of overdose and suicide deaths from data and forensic perspectives; and, (2) Combine said information with national insights and demonstrate how these occurrences are a public health emergency.}
1:30pm	Session #3 SKIN ISSUES & OTHER MANIFESTATIONS OF SUBSTANCE USE DISORDERS Dean A. Mayer, MD	_{After hearing this expert, participants will be able to:} _{(1) Recognize and assess skin issues and infections which may be presenting symptoms or later consequences of substance use disorders; and,} _{(2) Outline some of the other common manifestations of SUDs and explain the importance of their treatment.}
2:45pm	BREAK
3:00pm	Session #1 DIFFERENTIAL DIAGNOSIS, CO-MORBIDITY & TREATMENT OF PERSONALITY DISORDERS Eric Schmidt, LCSW, MBA	_{Practitioners often ask, “How do I tell if this person’s behavior is a result of a substance use disorder, personality disorder, both, or neither?” This presentation seeks to help attendees understand salient factors when diagnosing clients presenting with substance use and/or personality disorders, particularly Borderline PD. Eric Schmidt, a 24-year DBT practitioner, intensively trained in DBT and Linehan Board Certified DBT Clinician, will help answer these questions. He will also introduce participants to the DBT Substance Use Disorder protocols and skills. As a result of attending this session, participants will be able to: (1) Apply diagnostic criteria of substance use disorders and common personality disorders and ask salient questions to differentiate between these diagnoses; and, (2) DTeach clients DBT skills that address dual diagnosis.}
3:00pm	Session #2 WHO’S DRIVING THE BUS, AND WHERE ARE WE GOING? AN UPDATE ON PSYCHEDELIC SCIENCE IN ADDICTIONS Paul Thielking, MD	_{This speaker will provide an overview of psychedelics and their historical use, provide a review of the history of psychedelic medicine research including initial studies in the 1950s and 1960s, and describe the recent resurgence of interest in psychedelic medicines for a variety of conditions including substance use disorders. He will provide an update on recent research of medicines including psilocybin, MDMA, and Ketamine for substance use disorders. After listening to this expert, participants will be able to: (1) Trace the past and projected future use of psychedelics in treatment of addictions; and, (2) Detail the indications for use, expected outcomes, and other medical issues around treatments currently using psychedelics.}
3:00pm	Session #3 THE WAY WE WERE IS NOT THE WAY WE ARE: FEAR STALKS THE LAND – ARE WORKFORCE SHORTAGES TEMPORARY OR A NEW NORMAL? Jeffrey B. Jones, AICP Suggested readings for this session	_{Even as some workers return to the labor market as the pandemic recedes, underlying dynamics in the labor force indicate that labor supply shortages will persist. What impact has the opioid epidemic had on siphoning prime-age men out of the labor force? After attending this presentation, participants will be able to: (1) Trace the rise and fall of the state and national economic trends in recent years and discuss how these changes have impacted individuals and addiction use / abuse; and, (2) Explore the various theories about the current and future impact of our economy on the workforce and present creative ways some organizations are working to ‘survive’ in this changing and challenging time.}
4:15pm	END OF DAY TWO

Inclusion of faculty and content does not imply real or perceived endorsement by event hosts, partners, CE providers, organizers, planners, or any other parties affiliated with this event.

Conference Accreditation

Data & Reports

Agenda (with session objectives)

Psychiatry

WEDNESDAY, JUNE 1, 2022

OPTIONAL PRE-CONFERENCE WORKSHOP

THURSDAY, JUNE 2, 2022

FRIDAY, JUNE 3, 2022